CellaVision: The Growth Is Real, but It Isn't Coming From the Bone Marrow Story Yet

Q3 sales rose 13.6% on a Canadian tender and a Japanese reagent conversion; the FDA clearance and a new CEO's February strategy reset are still the catalysts that matter.

CEVI.ST · Earnings Call · 2026-10-29

A quarter carried by geography, not by the launch

CellaVision's Q3 2026 was its strongest top-line print in some time: net sales of SEK 200 million, up 13.6% reported and 13.4% organically, with EBITDA of SEK 64 million and a 32% margin. But the engines were geographic, not product-launch driven. The Americas grew 32% to SEK 89 million on demand for large connected instrument platforms, a notable software contribution, and a significant Canadian tender. APAC grew 91% organically. EMEA was still down 10% year over year against a tough comparison, though management stressed two consecutive quarters of sequential improvement after the Q1 distributor inventory correction. By product, instrument sales rose 14% to SEK 105 million, reagents 12% to SEK 45 million, and software and spare parts 15% to SEK 49 million. The named win was the tender in Canada, but management was careful to frame it as part of a mix of new business and instrument refreshes rather than a one-off sugar hit. That matters: the market has repeatedly asked whether Americas growth is pull-forward or genuine demand. The answer this quarter was "both, and we have visibility."

Bone marrow: revenue at last, but the guidance hasn't moved

The Bone Marrow Aspirate application has been the company's most-promoted product for at least three quarters. It topped the keyword list in 2025Q4 as generic "Bone Marrow" and stayed in the top 20 through 2026Q2. What is new in Q3 is not the product but the P&L: “The Bone Marrow Aspirate application has generated growing revenue in EMEA, and that's a meaningful milestone in our expansion into specialized microscopy.” — Steve Ferguson, Chief Executive Officer · 2026-10-29 That is a real milestone. It is also still small. Management said BMA should contribute roughly 1% to 2% of growth in the quarter. A year ago, in July, the language was almost identical: “we still hold our position that by year-end, the bone marrow sales should account to 1%-2% growth, that range.” — Steve Ferguson, Chief Executive Officer · 2026-07-17 Same target, same timeline. The FDA 510(k) review is still "ongoing," with the aim of clearance "before the end of this year"—identical to July's "by year-end." So the US launch remains a promise, not a surprise. The binary event is the clearance; until then, BMA is a European slow-build with a long evaluation cycle. Investors should treat the first EMEA revenue as proof of adoption, not as an upgrade to the near-term model.

The China fade and the EMEA recovery that keeps slipping

The sharpest contrast is geographic. In July, management said “the order book looks promising for EMEA. It looks like we have a strong order book for Q3 overall.” — Steve Ferguson, Chief Executive Officer · 2026-07-17 Q3 EMEA sales were still down 10% year over year. The company can fairly argue the comparison was tough and the Q1 inventory correction is over, but the recovery is slower than the July tone implied. Meanwhile, APAC's 91% growth is explicitly ex-China: “APAC grew 91% organically. Broad-based growth outside of China with solid performance for both instruments and reagents is the picture here.” — Steve Ferguson, Chief Executive Officer · 2026-10-29 China is now a headwind, not the growth market it was in prior calls: “globally that China is the market that's undergoing most pressure as government policy tries to drive cost from the healthcare system.” — Steve Ferguson, Chief Executive Officer · 2026-10-29 The offset is the conversion of the installed base to CellaVision reagents in Japan, where the company won a large national laboratory chain. That turns a one-off instrument placement into recurring reagent revenue. It is a commercial execution story, not a product story—and the CEO knows it.

We can take that as a cookie cutter and start to look at, right, where is the next region that we could replicate that in. But it's really down to commercial focus and strong execution there.
Steve Ferguson, Chief Executive Officer · 2026-10-29

Margins, R&D, and the February reset

Gross margin was 66%, down quarter over quarter, on higher amortization of capitalized development (SEK 5 million versus SEK 2 million) and a less favorable sales mix. The CFO was explicit that amortization "will stay on this level until we launch the next product," which means gross margin has a structural lid until the next-generation instruments arrive. Price increases from Q2 were fully in the Q3 number but only roughly tracked inflation: “they came in place from Q2, but we really see the full effect now in Q3... very rough following inflation.” — Monica Jonsson, Chief Financial Officer · 2026-10-29 R&D before capitalization was SEK 39 million, with SEK 16 million capitalized and SEK 23 million hitting the P&L; the CFO expects R&D to run at 20%-21% of sales rather than the 19% seen in Q3. That is a modest margin headwind, not a crisis. Cash remains robust at SEK 219 million, and operating cash flow was SEK 68 million. The forward catalyst is the Capital Markets Day on 17 February 2027 in Stockholm, where new CEO Steve Ferguson will present a revised strategy through 2030 and give more detail on the FPM technology and next-generation hematology analyzers. That innovation pipeline is the long-term option; the near-term numbers are still instruments, reagents, and software.

The quarter is a genuine improvement, but the story is not "bone marrow has arrived." It is "the base business is growing again outside China, and the new CEO gets a strategy reset in February." Watch three things: FDA clearance for BMA, a return to growth in EMEA, and whether the Japan reagent playbook travels to another region. If those line up, the February reset will have a stronger foundation than the Q3 headline alone suggests.